Raptiva and Urinary tract infection - a phase IV clinical study of FDA data

Summary:

Urinary tract infection is reported as a side effect among people who take Raptiva (efalizumab), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Humira, and have Pustular psoriasis.

The phase IV clinical study analyzes which people have Urinary tract infection when taking Raptiva. It is created by eHealthMe based on reports of 3,760 people who have side effects when taking Raptiva from the FDA, and is updated regularly.

What is Raptiva?

Raptiva has active ingredients of efalizumab. It is often used in psoriasis. eHealthMe is studying from 3,769 Raptiva users. Check the latest studies of Raptiva.

What is Urinary tract infection?

Urinary tract infection is found to be associated with 3,013 drugs and 3,956 conditions by eHealthMe. Check the latest studies of Urinary tract infection.

On Jul, 13, 2026

3,760 people reported to have side effects when taking Raptiva.
Among them, 18 people (0.48%) have Urinary tract infection.

Could Raptiva cause Urinary tract infection?

Among these 18 people:

How long have people been on Raptiva when they have Urinary tract infection? *

What is the gender of people who have Urinary tract infection when taking Raptiva? *

female: 58.82 %
male: 41.18 %

What is the age of people who have Urinary tract infection when taking Raptiva? *

What are other drugs people take besides Raptiva? *

What are other side effects people have besides Urinary tract infection? *

Anaemia (lack of blood): 4 people, 22.22%
Cervix Carcinoma (cancer of cervix): 4 people, 22.22%
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall): 2 people, 11.11%
Ankle Fracture: 2 people, 11.11%
Weight Decreased: 2 people, 11.11%
Kidney Infection: 2 people, 11.11%
Encephalitis Herpes (inflammation of the brain due to herpes infection): 2 people, 11.11%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 11.11%
White Blood Cell Count Decreased: 1 person, 5.56%
Eyelid Infection: 1 person, 5.56%

What are the existing conditions these people have? *

Pustular Psoriasis (raised bumps on the skin that are filled with pus): 4 people, 22.22%
Birth Control: 1 person, 5.56%
Acrodermatitis (skin condition that typically affects children between the ages of 6 months and 12 years): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Raptiva and have Urinary tract infection?

- Check whether Urinary tract infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Raptiva:

Raptiva (3,769 reports)

Browse all side effects of Raptiva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urinary tract infection:

Urinary tract infection (3,013 drugs)

Browse all the conditions that are associated with Urinary tract infection:

Urinary tract infection (3,956 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on efalizumab (the active ingredients of Raptiva) and Raptiva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.